Loading
CRISPR and Genetic Engineering / Cancer Research and Treatments · Journal article
Environmental Technology & Innovation · July 29, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review of CRISPR-Cas9 and alternative antimicrobial strategies for addressing antibiotic resistance. The source presents conceptual advantages and delivery challenges of CRISPR-Cas9 but reports no empirical efficacy data, clinical outcomes, or comparative evidence to support its use.
Journal article.
CRISPR-Cas9 is described as offering 'unprecedented precision in targeting AR genes' with 'selective disruption of resistance mechanisms within bacterial genomes while sparing the surrounding microbiota' Multiple delivery methods have been explored including electroporation, conjugative plasmid-mediated systems, bacteriophage-based viral vectors, and nanoparticle-mediated delivery Practical application of CRISPR-Cas9 as antimicrobial therapy is hindered by 'challenges in its effective delivery to bacterial cells'
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
This is a narrative review discussing CRISPR-Cas9 as a theoretical approach to antibiotic resistance, without reporting empirical clinical or experimental data, efficacy outcomes, or comparative evidence.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Antibiotic resistance (AR) emergence is a significant hazard to public health. The AR bacteria have driven the exploration of diverse alternative strategies, including antimicrobial peptides, bacteriocins, phage therapy, predatory bacteria, nanomaterials, phytochemicals, anti-quorum sensing agents, fecal microbial transplants, vaccines, antibodies, AI-driven tools, and CRISPR-Cas9. While each approach offers unique advantages, many face challenges, including stability, host specificity, toxicity, and scalability. Among these, CRISPR-Cas9 is a state-of-the-art technology that offers unprecedented precision in targeting AR genes. It enables selective disruption of resistance mechanisms within bacterial genomes while sparing the surrounding microbiota. However, the practical application of CRISPR-Cas9 as an antimicrobial therapy is hindered by challenges in its effective delivery to bacterial cells. Several delivery methods have been explored to address these challenges, including physical approaches like electroporation, conjugative plasmid-mediated systems, bacteriophage-based viral vectors, and nanoparticle-mediated delivery. These methods enhance the specificity and efficacy of CRISPR-based antimicrobials by ensuring precise delivery to target bacterial populations. This paper highlights the CRISPR-Cas9 system and its advanced delivery strategies, alongside a comprehensive review of the history of antibiotics, the emergence of resistance, and alternative antimicrobial approaches. By combining CRISPR-Cas9 with innovative delivery technologies, this next-generation platform offers a highly promising solution for addressing AR and advancing the treatment of infectious diseases.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.